These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 30881494)
1. Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3. Yuan T; Zhang F; Zhou X; Li Y; Zhang Y; Xu Y; Wang X Oncol Lett; 2019 Apr; 17(4):3719-3726. PubMed ID: 30881494 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression. Wang HQ; Liu BQ; Gao YY; Meng X; Guan Y; Zhang HY; Du ZX Br J Pharmacol; 2009 Nov; 158(5):1405-12. PubMed ID: 19681889 [TBL] [Abstract][Full Text] [Related]
3. [Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines]. Zhang TC; Chu HJ; Zhao JQ; Zhou XY; Shi DR Zhonghua Xue Ye Xue Za Zhi; 2010 Oct; 31(10):671-4. PubMed ID: 21223717 [TBL] [Abstract][Full Text] [Related]
4. [Effects of AKT protein kinase activation on biologic behavior of diffuse large B cell lymphoma cells]. Zhang TC; Zhou XY; Yu BH; Zhang TM; Shi DR Zhonghua Bing Li Xue Za Zhi; 2007 May; 36(5):318-23. PubMed ID: 17706139 [TBL] [Abstract][Full Text] [Related]
5. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313 [TBL] [Abstract][Full Text] [Related]
6. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954 [TBL] [Abstract][Full Text] [Related]
7. Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway. Jia X; Wen Z; Sun Q; Zhao X; Yang H; Shi X; Xin T J BUON; 2019; 24(5):1985-1991. PubMed ID: 31786865 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227 [TBL] [Abstract][Full Text] [Related]
9. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas. Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638 [TBL] [Abstract][Full Text] [Related]
10. Impact of MAPK and PI3K/AKT signaling pathways on Malabaricone-A induced cytotoxicity in U937, a histiocytic lymphoma cell line. Manna A; De Sarkar S; De S; Bauri AK; Chattopadhyay S; Chatterjee M Int Immunopharmacol; 2016 Oct; 39():34-40. PubMed ID: 27398613 [TBL] [Abstract][Full Text] [Related]
11. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465 [TBL] [Abstract][Full Text] [Related]
12. Targeting PIN-1 Attenuates GCB DLBCL Cell Proliferation Through Inhibition of PI3K/AKT Signaling. Yang H; Zhang P; Li J; Gao Y; Zhao L; Li J; Guo M; Zhang J; Li H; Wang F; Yuan Y Onco Targets Ther; 2020; 13():8593-8600. PubMed ID: 32904547 [TBL] [Abstract][Full Text] [Related]
13. microRNA-340 induces apoptosis by downregulation of BAG3 in ovarian cancer SKOV3 cells. Qu F; Wang X Pharmazie; 2017 Aug; 72(8):482-486. PubMed ID: 29441908 [TBL] [Abstract][Full Text] [Related]
14. Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Baohua Y; Xiaoyan Z; Tiecheng Z; Tao Q; Daren S Diagn Mol Pathol; 2008 Sep; 17(3):159-65. PubMed ID: 18382359 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma. Lv X; Feng L; Ge X; Lu K; Wang X J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma. Kim JH; Kim WS; Park C BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188 [TBL] [Abstract][Full Text] [Related]
17. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling. Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007 [TBL] [Abstract][Full Text] [Related]
18. PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer. Prasad SB; Yadav SS; Das M; Modi A; Kumari S; Pandey LK; Singh S; Pradhan S; Narayan G Cell Oncol (Dordr); 2015 Jun; 38(3):215-25. PubMed ID: 25821107 [TBL] [Abstract][Full Text] [Related]
19. Combination of cecropinXJ and LY294002 induces synergistic cytotoxicity, and apoptosis in human gastric cancer cells via inhibition of the PI3K/Akt signaling pathway. Xia LJ; Wu YL; Zhang FC Oncol Lett; 2017 Dec; 14(6):7522-7528. PubMed ID: 29344198 [TBL] [Abstract][Full Text] [Related]
20. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Li C; Liu VW; Chan DW; Yao KM; Ngan HY Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]